NCT06154291View on ClinicalTrials.gov

FIH XON7 in Advanced/Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

November 30, 2027

Conditions
Advanced Solid TumorMetastatic Cancer
Interventions
DRUG

XON7

The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration

Trial Locations (5)

1070

RECRUITING

Institut Jules Bordet, Anderlecht

31100

RECRUITING

IUCT-Oncopole, Toulouse

33076

RECRUITING

Institut Bergonié, Bordeaux

69003

RECRUITING

Centre Léon Bérard, Lyon

92150

RECRUITING

Hôpital Foch, Suresnes

All Listed Sponsors
lead

Xenothera SAS

INDUSTRY